A recent study by MSI PI Emil Lou (professor, Medicine; Masonic Cancer Center) and colleagues has shown that the protein GLS1 seems to be associated with better outcomes in patients with ovarian cancer. Previously, GLS1 had been considered as a drug target for cancer treatments. This study indicates that GLS1 may have a protective effect.
The study was published in the journal Cancer Research Communications and can be read on the journal’s website. An article about this research can be found on the U of M News site: U of M Researchers Discover Protein That May Be Associated With Better Prognosis for Women With Ovarian Cancer.
Professor Lou uses MSI resources for research into tunneling nanotubes, which may provide communications channels between cancer cells. This research was featured on the MSI website in March 2021: Identifying Tunneling Nanotubes With Machine Learning.